Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subconjunctival bevacizumab for recent-onset corneal neovascularisation
ISRCTN35052615Phase 3Completed
- Sponsor
- Moorfields Eye Hospital
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in corneal neovascularization (CNV) comparing Subconjunctival bevacizumab with Subconjunctival saline placebo (2 arms). Primary endpoint: Change in area of corneal neovascularisation. Started Apr 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on ISRCTN35052615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN35052615.